Study Details

Back to Search Results

A Study of ASP1951 in Subjects with Advanced Solid Tumors

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03799003

Astellas Study ID

The unique identification code given by the study sponsor.

1951-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2019-002287-27

Follow Trial

Condition

Advanced/Metastatic Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 Years - N/A

Sex

Female & Male

Product

ASP1951

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jan 2019 - Jul 2023

Masking

None (Open Label)

Enrollment number

120

A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP1951 in Subjects with Advanced Solid Tumors? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Multicare Regional Cancer Center Tacoma

Tacoma, United States, 98405

Comprehensive Cancer Nevada

Las Vegas, United States, 89169

South Texas Accelerated Research Therapeutics, LLC

San Antonio, United States, 78229

Virginia Cancer Specialists

Fairfax, United States, 22031

Emory University

Atlanta, United States, 30322

University of California

Sacramento, United States, 95817

Columbia University Medical Center

New York, United States, 10032

University of Iowa Hospitals

Iowa City, United States, 52242

Site KR82003

Seoul, Republic of Korea

Site KR82005

Daegu, Republic of Korea

Site KR82002

Chungcheongbukdo, Republic of Korea

Site KR82004

Seoul, Republic of Korea

Henry Ford Health System

Detroit, United States, 48202

Site TW88603

Taichung, Taiwan, Province of China

Augusta University

Augusta, United States, 30912

Rush University Medical Center

Chicago, United States, 60612

Rutgers Cancer Institute

New Brunswick, United States, 08903

University of Florida, Davis C

Gainesville, United States, 326102

Site TW88604

Taipei, Taiwan, Province of China

Site KR82007

Seoul, Republic of Korea

Site CA15002

Montreal, Canada

Site CA15005

Montreal, Canada

Hollings Cancer Center

Charleston, United States, 29425

Start Midwest

Grand Rapids, United States, 49546

Northwestern University

Chicago, United States, 60611

Icahn school of Medicine at Mount Sinai

New York, United States, 10029

Duke University Medical Center

Durham, United States, 27705

UC Irvine Medical Center

Orange, United States, 92868

Site KR82001

Gyeonggi-do, Republic of Korea

Site KR82006

Seoul, Republic of Korea

Nebraska Cancer Specialists

Omaha, United States, 68130

Arizona Clinical Research Cent

Tuscon, United States, 85715

Huntsman Cancer Institute

Salt Lake City, United States, 84112

Site CA15004

Ontario, Canada

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo